31.31 USD
-0.99 (-3.07%)
31.19 USD
-0.12 (-0.38%)
Overall GMAB gets a fundamental rating of 6 out of 10. We evaluated GMAB against 531 industry peers in the Biotechnology industry. GMAB gets an excellent profitability rating and is at the same time showing great financial health properties. GMAB has a correct valuation and a medium growth rate. These ratings could make GMAB a good candidate for quality investing.
1. Profitability
1.1 Basic Checks
In the past year GMAB was profitable.
GMAB had a positive operating cash flow in the past year.
Each year in the past 5 years GMAB has been profitable.
GMAB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of GMAB (21.10%) is better than 97.18% of its industry peers.
The Return On Equity of GMAB (25.76%) is better than 97.18% of its industry peers.
With an excellent Return On Invested Capital value of 17.11%, GMAB belongs to the best of the industry, outperforming 96.80% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for GMAB is below the industry average of 18.22%.
The 3 year average ROIC (15.20%) for GMAB is below the current ROIC(17.11%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROIC | 17.11% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
1.3 Margins
GMAB has a Profit Margin of 41.35%. This is amongst the best in the industry. GMAB outperforms 97.18% of its industry peers.
GMAB's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 36.85%, GMAB belongs to the best of the industry, outperforming 97.74% of the companies in the same industry.
GMAB's Operating Margin has declined in the last couple of years.
GMAB has a better Gross Margin (94.27%) than 94.73% of its industry peers.
In the last couple of years the Gross Margin of GMAB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% |
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
2. Health
2.1 Basic Checks
GMAB has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, GMAB has less shares outstanding
Compared to 5 years ago, GMAB has less shares outstanding
GMAB has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 11.97 indicates that GMAB is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 11.97, GMAB belongs to the best of the industry, outperforming 83.62% of the companies in the same industry.
The Debt to FCF ratio of GMAB is 0.12, which is an excellent value as it means it would take GMAB, only 0.12 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of GMAB (0.12) is better than 95.67% of its industry peers.
GMAB has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
GMAB has a Debt to Equity ratio of 0.02. This is comparable to the rest of the industry: GMAB outperforms 42.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Altman-Z | 11.97 |
ROIC/WACC2.47
WACC6.94%
2.3 Liquidity
A Current Ratio of 6.03 indicates that GMAB has no problem at all paying its short term obligations.
GMAB has a Current ratio of 6.03. This is in the better half of the industry: GMAB outperforms 62.90% of its industry peers.
A Quick Ratio of 6.01 indicates that GMAB has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.01, GMAB is in the better half of the industry, outperforming 63.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 |
3. Growth
3.1 Past
The earnings per share for GMAB have decreased strongly by -34.66% in the last year.
Measured over the past 5 years, GMAB shows a small growth in Earnings Per Share. The EPS has been growing by 0.56% on average per year.
Looking at the last year, GMAB shows a very strong growth in Revenue. The Revenue has grown by 24.66%.
GMAB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 31.16% yearly.
EPS 1Y (TTM)-34.66%
EPS 3Y-8.61%
EPS 5Y0.56%
EPS Q2Q%121.44%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-81.55%
3.2 Future
The Earnings Per Share is expected to decrease by -4.27% on average over the next years.
The Revenue is expected to grow by 13.32% on average over the next years. This is quite good.
EPS Next Y-48.21%
EPS Next 2Y-27.84%
EPS Next 3Y-13.19%
EPS Next 5Y-4.27%
Revenue Next Year22.77%
Revenue Next 2Y19.68%
Revenue Next 3Y17.4%
Revenue Next 5Y13.32%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 13.27, GMAB is valued correctly.
Compared to the rest of the industry, the Price/Earnings ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 96.61% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.54, GMAB is valued rather cheaply.
A Price/Forward Earnings ratio of 17.17 indicates a rather expensive valuation of GMAB.
GMAB's Price/Forward Earnings ratio is rather cheap when compared to the industry. GMAB is cheaper than 94.92% of the companies in the same industry.
GMAB is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.78, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.27 | ||
| Fwd PE | 17.17 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 96.42% of the companies listed in the same industry.
95.67% of the companies in the same industry are more expensive than GMAB, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.02 | ||
| EV/EBITDA | 10.8 |
4.3 Compensation for Growth
The decent profitability rating of GMAB may justify a higher PE ratio.
GMAB's earnings are expected to decrease with -13.19% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)23.69
EPS Next 2Y-27.84%
EPS Next 3Y-13.19%
5. Dividend
5.1 Amount
No dividends for GMAB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
31.31
-0.99 (-3.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners38.32%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap19.29B
Revenue(TTM)3.58B
Net Income(TTM)1.48B
Analysts73.33
Price Target41.78 (33.44%)
Short Float %1.91%
Short Ratio4.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.75%
Min EPS beat(2)25.14%
Max EPS beat(2)36.36%
EPS beat(4)4
Avg EPS beat(4)61.45%
Min EPS beat(4)25.14%
Max EPS beat(4)134.67%
EPS beat(8)6
Avg EPS beat(8)30.72%
EPS beat(12)8
Avg EPS beat(12)16.62%
EPS beat(16)12
Avg EPS beat(16)28.7%
Revenue beat(2)1
Avg Revenue beat(2)-0.2%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)1.09%
Revenue beat(4)2
Avg Revenue beat(4)-1.55%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)1.87%
Revenue beat(8)6
Avg Revenue beat(8)146.79%
Revenue beat(12)9
Avg Revenue beat(12)91.3%
Revenue beat(16)9
Avg Revenue beat(16)47.26%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)1.03%
EPS NQ rev (3m)6.08%
EPS NY rev (1m)3.9%
EPS NY rev (3m)9.44%
Revenue NQ rev (1m)-1.6%
Revenue NQ rev (3m)0.38%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)1.77%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.27 | ||
| Fwd PE | 17.17 | ||
| P/S | 5.38 | ||
| P/FCF | 16.02 | ||
| P/OCF | 15.13 | ||
| P/B | 3.35 | ||
| P/tB | 5.29 | ||
| EV/EBITDA | 10.8 |
EPS(TTM)2.36
EY7.54%
EPS(NY)1.82
Fwd EY5.82%
FCF(TTM)1.95
FCFY6.24%
OCF(TTM)2.07
OCFY6.61%
SpS5.82
BVpS9.34
TBVpS5.92
PEG (NY)N/A
PEG (5Y)23.69
Graham Number22.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROCE | 21.02% | ||
| ROIC | 17.11% | ||
| ROICexc | 37.46% | ||
| ROICexgc | 140.29% | ||
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% | ||
| FCFM | 33.59% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
ROICexc(3y)68.77%
ROICexc(5y)79.83%
ROICexgc(3y)104.16%
ROICexgc(5y)104.49%
ROCE(3y)18.68%
ROCE(5y)19.78%
ROICexgc growth 3Y22.66%
ROICexgc growth 5Y11.4%
ROICexc growth 3Y-22.7%
ROICexc growth 5Y-14.09%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Debt/EBITDA | 0.09 | ||
| Cap/Depr | 106.94% | ||
| Cap/Sales | 1.98% | ||
| Interest Coverage | 243.04 | ||
| Cash Conversion | 91.92% | ||
| Profit Quality | 81.24% | ||
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 | ||
| Altman-Z | 11.97 |
F-Score7
WACC6.94%
ROIC/WACC2.47
Cap/Depr(3y)96.21%
Cap/Depr(5y)101.76%
Cap/Sales(3y)1.96%
Cap/Sales(5y)2.38%
Profit Quality(3y)107.36%
Profit Quality(5y)103.53%
High Growth Momentum
Growth
EPS 1Y (TTM)-34.66%
EPS 3Y-8.61%
EPS 5Y0.56%
EPS Q2Q%121.44%
EPS Next Y-48.21%
EPS Next 2Y-27.84%
EPS Next 3Y-13.19%
EPS Next 5Y-4.27%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-81.55%
Revenue Next Year22.77%
Revenue Next 2Y19.68%
Revenue Next 3Y17.4%
Revenue Next 5Y13.32%
EBIT growth 1Y41.76%
EBIT growth 3Y29.8%
EBIT growth 5Y21.02%
EBIT Next Year53.73%
EBIT Next 3Y29.06%
EBIT Next 5Y18.11%
FCF growth 1Y46.62%
FCF growth 3Y51.06%
FCF growth 5Y42.84%
OCF growth 1Y44.68%
OCF growth 3Y47.08%
OCF growth 5Y41.48%
GENMAB A/S -SP ADR / GMAB FAQ
What is the ChartMill fundamental rating of GENMAB A/S -SP ADR (GMAB) stock?
ChartMill assigns a fundamental rating of 6 / 10 to GMAB.
What is the valuation status of GENMAB A/S -SP ADR (GMAB) stock?
ChartMill assigns a valuation rating of 6 / 10 to GENMAB A/S -SP ADR (GMAB). This can be considered as Fairly Valued.
Can you provide the profitability details for GENMAB A/S -SP ADR?
GENMAB A/S -SP ADR (GMAB) has a profitability rating of 7 / 10.
What is the valuation of GENMAB A/S -SP ADR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for GENMAB A/S -SP ADR (GMAB) is 13.27 and the Price/Book (PB) ratio is 3.35.
What is the earnings growth outlook for GENMAB A/S -SP ADR?
The Earnings per Share (EPS) of GENMAB A/S -SP ADR (GMAB) is expected to decline by -48.21% in the next year.